Retatrutide (LY3437943) is an investigational triple-hormone receptor agonist developed by Eli Lilly
For patients with excessive skin laxity, surgery may be the best option
Clinical trial data is cited with full attribution to the source study and explicitly applies to the FDA-approved active ingredient in the studied trial population - not as a guarantee of identical results from compounded formulations or for any individual patient
Treatment persistence in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists in clinical practice in Sweden
Think: hollowed cheeks and temples, sagging skin along the jawline and neck, sunken or dark under-eye circles, and worsened wrinkles
Nonetheless, the net effect from the meta-analysis supports the combined therapy, although it exhibits considerable heterogeneity and includes very few studies